Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 656 of 5804
-
Could a shorter course of blood thinners be safer after a heart attack?
Disease control Recruiting nowThe study is a multi-centre, Open-label, Randomized Controlled, 1:1 trial comparing Prasugrel-based short DAPT (30-45 days) followed by Prasugrel monotherapy versus standard DAPT regimen in STEMI patients in terms of safety and efficacy endpoints. In the subgroup of STEMI patien…
Phase: PHASE4 • Sponsor: Research Maatschap Cardiologen Rotterdam Zuid • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug cocktail shows promise for tough bile duct cancer
Disease control CompletedThe goal of this clinical trial is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) combined with tislelizumab and regorafenib as first-line therapy in patients with locally advanced or metastatic cholangiocarcinoma. The main questions it aims…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Zhengzhou University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope in blood cancer battle: Next-Gen drug tested against standard therapy
Disease control Recruiting nowThe purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part 2 of this study evaluates pirtobrutinib m…
Phase: PHASE3 • Sponsor: Loxo Oncology, Inc. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Double biologic punch: new combo therapy for Crohn's shows promise in Mid-Stage trial
Disease control OngoingThe purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New hope for tough lung cancer: LAGOON trial tests powerful drug combo
Disease control CompletedMulticenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of two experimental arms consisting of lurbinectedin as single agent (Group A) or the combination of lurbinectedin with irinotecan (Group B) versus Investigato…
Phase: PHASE3 • Sponsor: PharmaMar • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New drug cocktail aims to wipe out breast cancer before surgery
Disease control Recruiting nowPatient will be treated with neratinib, an aromatase inhibitor and trastuzumab for 24 weeks prior to surgery, following an initial 3 weeks of neratinib alone, aromatase inhibitor alone or the combination of neratinib and an aromatase inhibitor. A breast biopsy will be performed p…
Phase: PHASE2 • Sponsor: Ruth O'Regan • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Immunotherapy drug shows promise against deadly thyroid cancer
Disease control OngoingThis phase II trial tests whether vudalimab works to shrink tumors in patients with anaplastic thyroid cancer or hurthle cell thyroid cancer that has spread to nearby tissue or lymph nodes (locally advanced) or has spread to other places in the body (metastatic). Immunotherapy wi…
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New cocktail aims to keep High-Risk myeloma at bay
Disease control Recruiting nowThis phase II trial studies the effect of belantamab mafodotin, pomalidomide, and dexamethasone in treating patents with high-risk myeloma. Belantamab mafodotin is a monoclonal antibody, called belantamab, linked to a chemotherapy drug, called mafodotin. Belantamab is a form of t…
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 26, 2026 13:22 UTC
-
New drug cocktail shows promise for Hard-to-Treat blood cancers
Disease control OngoingThe purpose of this study is to assess the safety and tolerability of zilovertamab vedotin as monotherapy and in combination in participants with select B-cell lymphomas including mantle cell lymphoma (MCL), Richter's transformation lymphoma (RTL), follicular lymphoma (FL), and c…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Singapore study aims to catch lung cancer earlier with CT scans and blood tests
Diagnosis Recruiting nowThis is a single arm screening study. All eligible participants will be subjected to low dose CT (LDCT) screening and biomarker testing. The primary aim of the study is to determine the feasibility of conducting LDCT screening in at-risk populations for lung cancer in Singapore:…
Phase: NA • Sponsor: National Cancer Centre, Singapore • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC
-
Radioactive antibody hones in on cancer cells to boost transplant success
Disease control OngoingThis phase I trial is to find out the best dose, possible benefits and/or side effects of 90Y-DOTA-anti-CD25 basiliximab given together with fludarabine, melphalan, and total marrow and lymphoid irradiation (TMLI) in treating patients with high-risk acute leukemia or myelodysplas…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New four-drug cocktail shows promise for hard-to-treat myeloma
Disease control OngoingThe primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with nirogacestat, lenalidomide, and dexamethasone, and to establish the recommended Phase 2 dose for combination treatment to explore in the cohort expansion (CE) phase in part…
Phase: PHASE1, PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo aims to shrink Hard-to-Treat colorectal tumors
Disease control OngoingThis phase II trial tests whether adding nivolumab to the usual treatment (encorafenib and cetuximab) works better than the usual treatment alone to shrink tumors in patients with colorectal cancer that has spread to other places in the body (metastatic) or that cannot be removed…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New hope for tough lung cancer: onvansertib trial targets relapsed small cell
Disease control Recruiting nowThis phase II clinical trial will study the safety and efficacy of onvansertib to treat patients with small cell lung cancer (SCLC) who have either not responded to or are unable to tolerate chemotherapy. Onvansertib is a drug that inhibits polo-like kinase 1 (PLK-1), an enzyme t…
Phase: PHASE2 • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New hope for Hard-to-Treat cancers: DB-1305 enters human trials
Disease control OngoingThis is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1305/BNT325 in subjects with advanced solid tumors.
Phase: PHASE1, PHASE2 • Sponsor: DualityBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Can lowering cholesterol more aggressively help seniors with heart disease?
Disease control OngoingAlthough there have been studies regarding intensive lowering of low-density lipoprotein (LDL)-cholesterol with high intensity statins in patients with cardiovascular disease, elderly patients were either excluded or accounted only a small portion of study subjects. Therefore, th…
Phase: PHASE4 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo therapy aims to slow advanced breast cancer growth
Disease control OngoingThis Phase III, randomized, two-arm, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus Phesgo compared with Phesgo after induction therapy with Phesgo plus taxane in participants with human epidermal growth factor receptor 2 (HER2)-positive,…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Immunotherapy plus chemo shows promise against tough throat cancer
Disease control OngoingThe purpose of this Phase II, Multicenter, Randomized Controlled Clinical Trial is to evaluate the efficacy and safety of PD-1 inhibitor Plus GP chemotherapy as Neoadjuvant Therapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma.
Phase: PHASE2 • Sponsor: Guangxi Medical University • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Could a simple supplement make chemo work better for advanced colon cancer?
Disease control CompletedThe goal of this clinical trial is to learn if adding sodium nucleinate to FOLFOX chemotherapy helps people with metastatic colorectal cancer (colon or rectal cancer that has spread). Researchers will also look at side effects and how people feel during treatment. The main quest…
Phase: PHASE2, PHASE3 • Sponsor: MIPO Clinic • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
AI could spot sepsis earlier from routine hospital data
Diagnosis Recruiting nowRetrospective observational study to develop a Machine Learning Algorithm to evaluate parameters collected from routine data for the diagnosis of sepsis and septic shock and their influence on time to diagnosis and patient outcome.
Sponsor: Charite University, Berlin, Germany • Aim: Diagnosis
Last updated Jun 27, 2026 08:00 UTC